Boston Scientific
- Home
- Companies
- Boston Scientific
- Products
- DC BeadM1 - Hydrogel Microspheres
DC BeadM1 - Hydrogel Microspheres
DC BeadM1 has been developed with a narrower distribution and offers the proven benefits of DC BeadM1 to more patients. Effective at penetrating metastatic tumors and avoiding premature proximal occlusion of tumour-feeding vessels. May allow for more concentrated drug delivery within the tumour and greater tumoural devascularisation. May allow the doctor to be more selective and target only the vessels feeding the tumour and so protect the healthy liver and reduce stress to cirrhotic liver. Allows for full dosing without premature endpoint.
Unique size range, elution profile and distribution.
Most popular related searches
DC BeadM1 is intended to be loaded with doxorubicin for the purpose of:
- Embolisation of vessels supplying malignant hypervascularised tumour(s)
- Delivery of a local, controlled, sustained dose of doxorubicin to the tumour(s)
DC BeadM1 in intended to be loaded with irinotecan for the purpose of:
- Embolisation of vessels supplying malignant colorectal cancer metastasised to the liver (mCRC)
- Capable of eluting a local, controlled, sustained dose of irinotecan to hepatic metastases of colorectal cancer